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The fibrin agarose plate assay is widely used in the detection of thrombolysis efficacy. However, a rigorous mathematical model 
for analyzing data or comparing activities of different thrombolytics has been absent. This study investigated the relationship be-
tween thrombolysis radius, R, and diffusion time, t, of molecular medicines in an agarose hydrogel system by deriving a model 
based on Fick’s law and experimental verification by the fibrin agarose plate assay method. The theoretical results showed that a 
plot of log(R) versus log(t) has a linear curve with the slope of 1/2 and this was verified by experimental results using urokinase as 
a modeling agent. Moreover, it was found that 
R
t
 is constant for a specific thrombolytic and can be used as a parameter for 
evaluating activities of different thrombolytics. The theoretical model has potential for improving the understanding of mecha-
nisms involved in molecular medicine diffusion and offers benefits for thrombolytic therapy. 
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Thrombosis, such as acute myocardial infarction [1], pul-
monary embolism [2], ischemic stroke [3] and peripheral 
arterial occlusions [4], is a severe clinical condition in which 
thrombus forms in a critical blood vessel [5]. Thrombolytic 
therapy has been a major treatment of thrombosis to date, 
using thrombolytics such as streptokinase (SK) [6], uroki-
nase (UK) [7] or its mutant [8] and tissue type plasminogen 
activator (t-PA) [3,7] to dissolve thrombi. The assessment 
of thrombolytic activity, therefore, is of fundamental con-
cern for the quality control of existing drugs and the devel-
opment of new drugs.  
To date, the fibrin agarose plate assay (FAPA) has been 
widely used to determine the fibrinolytic activity of throm-
bolytics, due to its good reproducibility, specificity, low 
cost and high sensitivity [9]. The general procedure of 
FAPA is to inject thrombolytic agents such as SK, UK or 
t-PA, into a fibrin agarose plate. The thrombolytics then 
directly catalyze the conversion of plasminogen into plas-
min that, in turn, degrades fibrin and subsequently leads to 
the appearance of fibrinolytic discs in the agarose gel plate. 
By measuring the diameters of the fibrinolytic discs at a 
certain time point, activities of the tested thrombolytic agents 
are obtained. 
However, interpretation of the data for fibrinolytic discs 
and activity comparisons between drugs cannot be properly 
conducted because of the absence of a rigorous mathemati-
cal theory or standard. Therefore, establishing a mathemat-
ical computing model is of critical importance.  
In this paper, we describe a new mathematical model for 
the thrombolytic activity assay, based on Fick’s law. The 
solution of the model generated theoretical predictions for 
the diameters of the fibrinolytic discs, which were then con-
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firmed by experiments using UK as the modeling agent. 
Based on these theoretical analyses, a general rule was pro-
posed to compare the activities of different thrombolytics by 
the FAPA method. This study may provide a theoretical 
reference for thrombolytic therapy and is expected to be 
applicable for the evaluation of drugs in the treatment of 
thrombosis. 
1  Theoretical analysis of the FAPA process 
1.1  Physical description 
Figure 1 depicts the physical model of the FAPA process. 
Figure 1(a) is the planform of the agarose plate. The throm-
bolytic agent is injected at initial concentration (C0) into the 
small hole located at the center of the plate (denoted as the 
sample pool), where the concentration of the thrombolytic 
remains highest during the whole measurement process. The 
concentration difference in and around the sample pool will 
generate a driving force for the diffusion of the drug along 
the plate. If the diffusion channels within the plate are uni-
formly distributed, a net diffusion flux will be generated 
only along the radial direction. For every small unit volume 
(Figure 1(b)), the difference between the amount of drug 
flowing in and out must be used to increase the drug con-
centration within the volume. This will cause a change in 
concentration and a shift in the concentration gradient in the 
radial direction with time. The fibrinolytic disc (the shaded 
part in Figure 1(a) and (c)) front corresponds to the position 
where fibrin can be dissolved by the minimum drug con-
centration (Cmin) (Figure 1(a) and (c)). The distance from 
the disc front to the center of the sample pool is the radius  
(R) of the fibrinolytic disc. 
1.2  Mathematical model 
The concentration (C) of drug in the plate is expected to be 
a function of diffusion time (t) and the distance from the 
sample pool (x). Several assumptions are made, as follows, 
to establish the mathematical model:  
(1) the agarose plate medium (Figure 1(a)) is homoge-
neous;  
(2) the diffusion of drugs in plate is symmetrical;  
(3) the sample pool is indefinitely small;  
(4) the initial highest concentration (C0) does not vary 
with t; and 
(5) drug diffusion follows Fick’s second law.  
As depicted in Figure 1(b) (J is the diffusion flux,     
kg m2 s1), Fick’s second law of diffusion in one dimension 
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where D is the diffusion coefficient (m2/s); C (x, t) is con-
centration (kg/m3); t is time (s); and x is the distance (m) 
from the center of the disc or sample pool. 
The solution of this equation is in the form (see Appen-
dix 1 for the detailed derivation of the formula): 
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The initial condition for our drug diffusion agarose gel 
system is,  
 
Figure 1  Schematic diagram of thrombolytic diffusion in an agarose plate. (a) Planform; (b) a small unit volume and (c) one-dimensional view of the dif-
fusion system. The shaded part indicates the fibrinolytic disc, C0 and Cmin are the initial concentration and the minimum fibrin dissolution concentration of 
the drug, respectively. J is the diffusion flux. 
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and the boundary condition is 
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     1 , (5) 
as the concentration distribution of thrombolytics with radi-
al distance and time, as depicted in Figure 2(a) and (b). 
Clearly, when C0 is constant, the graph shows that C(x, t) 
decreases with distance x (Figure 2(a)) but increases with 
incubation time (Figure 2(b)). 
Because the dissolution front of the fibrinolytic disc cor-
responds to the position where the drug concentration equals 
Cmin, we can obtain the exact value of the R by replacing 
C/C0 with Cmin/C0 in the simulation curve of C/C0~x in Fig-
ure 2(a). That is to say, when C=Cmin, x=R. Different rela-
tionships between R and t can be seen for different Cmin of 
thrombolytics (Figure 2(c)). A more rapid increase in R with 
time corresponds to a lower Cmin, which indicates a higher 
thrombolytic activity. This is consistent with the FAPA 
measurement and the model clearly provides a theoretical 
explanation. 
1.3  Predictions of the mathematical model  
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For a given C0 and specific thrombolytics, Cmin is a constant. 









are also constants.  
Suppose the constant 
R
Dt
is K, the relation between R 
and t is 
 
1
log( ) log( )
2
R t M  , (7) 
where M=  1/2log( ) logK D . Eq. (7) predicts that log(R) 
versus log(t) has a linear relationship with a slope of 1/2 and 
an intercept of M, as shown in Figure 3(a).  
From eq. (6), we further predicted that, first, for the same 
drug with the same Cmin, a sample with a higher initial con-




larger intercept, M, i.e.,  
 
Figure 2  (Color online) Theoretical concentration, C, distribution of 
thrombolytics with (a) radial distance x and (b) diffusion time t, as well as 
(c) the theoretical values of the radii, R, of fibrinolytic discs using drugs 
with different activities (Cmin<C′min).  
 min min 0 0( ; )M M C C C C     , (8) 
as shown in Figure 3(b). Second, a drug with a higher spe-
cific activity (lower Cmin value) will present a higher con-




  when C0 and D remain constant, 
i.e.,  
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Figure 3  (Color online) Theoretical curves of the relationships between 
the radius R of the fibrinolytic discs and diffusion time t. (a) log(R) versus 
log(t) of a drug; (b) log(R) versus log(t) of a drug with two different initial 
concentrations (C0>C′0); (c) R
t
~ t of two drugs with different activities 
(Cmin<C′min). 
 min min 0 0( ;  )
R R
n n C C C C
t t
        , (9) 
as shown in Figure 3(c). 




be directly used to evaluate the activity of thrombolytics. 
The higher value of 
R
t
, the higher the activity of the drug. 
This prediction is significant because it can be used to set 
up a new and general standard for FAPA testing.  
2  Experimental verification and discussion 
2.1  Materials and methods 
The fibrin plate assay with some modifications was used to 
determine the UK activity [12]. For the preparation of fibrin 
plates, a 0.6% (wt/vol) agarose solution (21 mL), 5% (wt/vol) 
bovine fibrinogen (2 mL; Institute of Food and Drug Test), 
1.2 units/mL of bovine plasminogen (1 mL; Institute of 
Food and Drug Test), and 15 units/mL of thrombin (1 mL; 
Sigma) in 100 mmol/L PBS buffer (pH 7.4) were mixed in a 
Petri dish (diameter, 90 mm). Serial dilutions of the UK 
sample (2.5, 5, 12.5, 25 and 50 mg/L in 0.9% NaCl solution, 
approximately 10 L) were injected into sample pools in the 
fibrin plate and incubated at 37°C for 1, 2, 4, 6, 8, 12 and  
24 h. To compare the activities of different drugs, we chose 
two kinds of UK from different producers (Dillon Pharma-
ceutical Co., Ltd. in Heilongjiang, China with a batch num-
ber 20090517 and Livzon Pharmaceutical Group Inc. in 
Guangdong, China with a batch number 100804) which we 
determined to have different activities (Dillon UK displayed 
the higher specific activity, data not shown). Diameters of 
the fibrinolytic discs were measured by Vernier caliper. To 
eliminate the influence of temperature during the testing 
process, we completed the measurement in an incubator 
(Yiheng Technology Co., Ltd., Shanghai, China) which 
provided a constant temperature of 37°C. Images of fibri-
nolytic discs at each time point (1, 2, 4, 6, 8, 12 and 24 h) 
were collected within several seconds. 
2.2  Verification of equations (7)–(9) 
Images of the fibrinolytic discs in the agarose hydrogel sys-
tem are displayed in Figure 4. It is shown that the areas of 
the fibrinolytic discs for both UKs increased with incuba-
tion time and were proportional to the initial concentration 
of UK. Figure 5(a) and (b) depicts the correlations between 
log(R) and log(t) according to the experimental results. 
Comparing these with the predictions using eqs. (7) and (8), 
the experimental curves were in good agreement with the 
theoretical curves shown in Figure 3(a) and (b) for both 
UKs with different specific activities. The slopes of the 
curves in Figure 5(a) and (b) were between 0.503 and 0.551, 
which are very close to 1/2. Deviations in the experimen-
tally determined slopes from the theoretical prediction may 
be caused by the assumption in the model that the concen-
tration in the sample pool remains unchanged throughout 
the FAPA process. Figure 5(a) and (b) also verified the pre-
diction of eq. (8), where the intercepts of the curves increased  
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Figure 4  Thrombolysis efficacy images of (a) Dillon and (b) Livzon UKs at different incubation times. Dillon UK displayed a higher specific activity, as 
determined by the BCA method. 
 
Figure 5  (Color online) Experimental curves of the relationships between 
the radius, R, of fibrinolytic discs and incubation time, t. (a) log(R) versus 




for Dillon and Livzon UKs.  
with the initial UK concentrations. 




with time for the two UKs. For both drugs, with the same 
initial concentration, the values of 
R
t
 are constants, 
which is in good agreement with the theoretical eq. (9) and 
the theoretical curves in Figure 3(c). Furthermore, by com-
paring the two drugs, we conclude that the UK with higher 




 , which 





  is confirmed as a useful parameter for evalu-
ating activities of different enzymes. 
2.3  Discussion 
We developed theoretical relationships between the fibri-
nolysis radius and the diffusion time of drugs in the FAPA 
process using Fick’s second law. Experimental results in 
Figure 5 successfully verified these relationships. These 
findings provide a theoretical foundation for FAPA testing 
and have significance in its application. First, the linearity 
of the curve of log(R) versus log(t) can be used to check the 
fidelity of FAPA testing. The linear correlation factors for 
all the curves in Figure 5 were over 0.99, indicating a high 
credibility of the test. 
Second, if the value of Cmin is measured, the diffusion 
coefficient D can be calculated more conveniently using eq. 
(6), circumventing complicated calculations using formulae 
involved in molecular diffusion models such as the steric 
effect model [13–15] and more comprehensive models 
[16–18].  
Third, our theoretical and experimental results show that 
R
t
can be used as a parameter for comparing the activities 
of different thrombolytics. This finding greatly improves the 
3238 Wang M Q, et al.   Chin Sci Bull   August (2012) Vol.57 No.24 
power of the FAPA method for thrombolytic activity as-
sessment. It may be used for the quality control of existing 
drugs and the development of new drugs.  
3  Conclusion 
A theoretical model providing the relationship between 
thrombolysis radius, R, and UK diffusion time, t, was estab-
lished based on the Fick’s second law and verified by ex-
perimental results. It is revealed that there is a linear log(R) 
versus log(t) curve with a slope close to 1/2 and a constant 
R
t




value can be used as a parameter for the evalu-
ation of activities of different thrombolytics. These new 
findings may provide insights into thrombolytic testing and 
improve FAPA measurements.  
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Appendix 1  Detailed derivation of the formula 
 
The supporting information is available online at csb.scichina.com and www.springerlink.com. The supporting materials 
are published as submitted, without typesetting or editing. The responsibility for scientific accuracy and content remains en-
tirely with the authors. 
 
 
